SEARCH

SEARCH BY CITATION

References

  • 1
    Colozza M, Azambuja E, Cardoso F, et al. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005; 16: 172339.
  • 2
    Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 2006; 8: 216.
  • 3
    Barak V, Goike H, Panaretakis KW, et al. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004; 37: 52940.
  • 4
    Bonfrer JM, Groeneveld EM, Korse CM, et al. Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18. Tumour Biol 1994; 15: 21022.
  • 5
    Rydlander L, Ziegler E, Bergman T, et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 1996; 241: 30914.
  • 6
    D'Alessandro R, Roselli M, Ferroni P, et al. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15–3 in the management of breast cancer. Breast Cancer Res Treat 2001; 68: 919.
  • 7
    O'Hanlon DM, Kerin MJ, O'Boyle C, et al. Tissue polypeptide specific antigen (TPS) in breast cancer—an initial evaluation. Eur J Surg Oncol 1996; 22: 3841.
  • 8
    Van Dalen A, Barak V, Cremaschi A, et al. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. Int J Biol Markers 1998; 13: 1015.
  • 9
    Schuurman JJ, Bong SB, Einarsson R. Determination of serum tumor markers TPS and CA 15–3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res 1996; 16: 216972.
  • 10
    Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 2008; 54: 17709.
  • 11
    Park BW, Oh JW, Kim JH, et al. Preoperative CA 15–3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008; 19: 67581.
  • 12
    Molina R, Jo J, Filella X, et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998; 51: 10919.
  • 13
    Ebeling FG, Stieber P, Untch M, et al. Serum CEA and CA 15–3 as prognostic factors in primary breast cancer. Br J Cancer 2002; 86: 121722.
  • 14
    McLaughlin R, McGrath J, Grimes H, et al. The prognostic value of the tumor marker CA 15–3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 2000; 15: 3402.
  • 15
    Weber K, Osborn M, Moll R, et al. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMBO J 1984; 3: 270714.
  • 16
    Bjorklund B, Bjorklund V. Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique; presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy Appl Immunol 1957; 10: 15384.
  • 17
    Bjorklund B. Tumor-markers TPA, TPA-S and cytokeratins—a working hypothesis. Tumordiagn Ther 1992; 13: 7880.
  • 18
    Bodenmuller H, Ofenloch-Hahnle B, Lane EB, et al. Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21–1. Int J Biol Markers 1994; 9: 7581.
  • 19
    Given M, Scott M, Mc Grath JP, et al. The predictive of tumour markers CA 15–3, TPS and CEA in breast cancer recurrence. Breast 2000; 9: 27780.
  • 20
    Bottini A, Berruti A, Tampellini M, et al. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15–3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. Tumour Biol 1997; 18: 30110.
  • 21
    Hwa HL, Kuo WH, Chang LY, et al. Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models. J Eval Clin Pract 2008; 14: 27580.
  • 22
    Barak V, Nisman B, Roisman I, et al. TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons. J Tumor Marker Oncol 1997; 12: 1725.
  • 23
    Dai H, van't Veer L, Lamb J, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005; 65: 405966.
  • 24
    Ahn SH, Son BH, Kim SW, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol 2007; 25: 23608.
  • 25
    van Dalen A. TPS in breast cancer—a comparative study with carcinoembryonic antigen and CA 15–3. Tumour Biol 1992; 13: 1017.
  • 26
    Inaba N, Fukasawa I, Okajima Y, et al. Immunoradiometrical measurement of tissue polypeptide specific antigen (TPS) in normal, healthy, nonpregnant and pregnant Japanese women. Asia Oceania J Obstet Gynaecol 1993; 19: 45966.